ArticleJournal of immunology (Baltimore, Md. : 1950)2008
E47 controls the developmental integrity and cell cycle quiescence of multipotential hematopoietic progenitors.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 70 citations in OpenAlex.
- B-lineage commitment is dependent on a reversible epigenetic switch.Genes & development · 2026Article
- A prevalent disease-associated SNP in the humanNAR molecular medicine · 2026Article
- The Function of E2A in B-Cell Development.Advances in experimental medicine and biology · 2024Review
- Early B-Cell Factor 1: An Archetype for a Lineage-Restricted Transcription Factor Linking Development to Disease.Advances in experimental medicine and biology · 2024Review
- Transcription factor networks link B-lymphocyte development and malignant transformation in leukemia.Genes & development · 2023Review
- Editorial: Molecular switches of the immune system: The E-protein/Id axis in hematopoietic development and function.Frontiers in immunology · 2022Article
- E Protein Transcription Factors as Suppressors of T Lymphocyte Acute Lymphoblastic Leukemia.Frontiers in immunology · 2022Review
- The telomere complex and the origin of the cancer stem cell.Biomarker research · 2021Review
- How transcription factors drive choice of the T cell fate.Nature reviews. Immunology · 2021Review
- Cutting Edge: Lymphomyeloid-Primed Progenitor Cell Fates Are Controlled by the Transcription Factor Tal1.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- The Concerted Action of E2-2 and HEB Is Critical for Early Lymphoid Specification.Frontiers in immunology · 2019Article
- Bone marrow transcriptome and epigenome profiles of equine common variable immunodeficiency patients unveil block of B lymphocyte differentiation.Clinical immunology (Orlando, Fla.) · 2015Article
- Cutting Edge: Hematopoietic Stem Cell Expansion and Common Lymphoid Progenitor Depletion Require Hematopoietic-Derived, Cell-Autonomous TLR4 in a Model of Chronic Endotoxin.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Repression of Ccr9 transcription in mouse T lymphocyte progenitors by the Notch signaling pathway.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Requirement for ssbp2 in hematopoietic stem cell maintenance and stress response.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Hematopoiesis in steady-state versus stress: self-renewal, lineage fate choice, and the conversion of danger signals into cytokine signals in hematopoietic stem cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Review
- The regulatory network of B-cell differentiation: a focused view of early B-cell factor 1 function.Immunological reviews · 2014Review
- Smurf2 regulates hematopoietic stem cell self-renewal and aging.Aging cell · 2014Article
- Cell-intrinsic in vivo requirement for the E47-p21 pathway in long-term hematopoietic stem cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- E2A predicts prognosis of colorectal cancer patients and regulates cancer cell growth by targeting miR-320a.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Little is known about the transcriptional regulators that control the proliferation of multipotent bone marrow progenitors. Understanding the mechanisms that restrict proliferation is of significant interest since the loss of cell cycle integrity can be associated with hematopoietic exhaustion, bone marrow failure, or even oncogenic transformation. Herein, we show that multipotent LSKs (lineage(-)Sca(high)c-kit(+)) from E47-deficient mice exhibit a striking hyperproliferation associated with a loss of cell cycle quiescence and increased susceptibility to in vivo challenge with a mitotoxic drug. Total LSKs contain long-term self-renewing hematopoietic stem cells and downstream multipotential progenitors (MPPs) that possess very limited or no self-renewal ability. Within total LSKs, we found specific developmental and functional deficits in the MPP subset. E47 knockout mice have grossly normal numbers of self-renewing hematopoietic stem cells but a 50-70% reduction in nonrenewing MPPs and downstream lineage-restricted populations. The residual MPPs in E47 knockout mice fail to fully up-regulate flk2 or initiate V(D)J recombination, hallmarks of normal lymphoid lineage progression. Consistent with the loss of normal cell cycle restraints, we show that E47-deficient LSKs have a 50% decrease in p21, a cell cycle inhibitor and known regulator of LSK proliferation. Moreover, enforced expression studies identify p21 as an E47 target gene in primary bone marrow LSKs. Thus, E47 appears to regulate the developmental and functional integrity of early hematopoietic subsets in part through effects on p21-mediated cell cycle quiescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.